Schizophrenia
2,936
193
234
2,031
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
679 trials with published results (23%)
Research Maturity
2031 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.3%
213 terminated out of 2936 trials
90.5%
+4.0% vs benchmark
27%
792 trials in Phase 3/4
33%
679 of 2031 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2031 completed trials
Clinical Trials (2936)
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Metformin Treatment on Cognitive Impairment of Schizophrenia
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
Mechanisms Evaluating Striatal Systems Imaging: LIFU Effects & Outcomes
52-week Open Label Safety-Tolerability Study
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome
Tele-group Cognitive Behavioural Family Intervention for People With Schizophrenia and Their Families (Feasibility tgCBFI)
Prebiotic Treatment in People With Schizophrenia
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia